Print

AVEG 201

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant Subunit HIV-1 Envelope Vaccines SF-2 RGP120 in MF59 (Biocine) and MN rgp120 in Alum (Genentech)

Trial Details:

II Completed
National Institute of Allergy and Infectious Diseases (NIAID) December 09, 1992
rgp120/HIV-1 SF-2,MN rgp120 Env gp120 B SF-2; Env gp120 B MN
rgp120/HIV-1 SF-2 Protein
MN rgp120 Protein
USA 296
NCT00001031
https://clinicaltrials.gov/show/NCT00001031